University of South Carolina Libraries
In diplomatic talks, U.S. to push China for return of spy plane by Christopher Bodeen Associated Press BEUING — Teams of U.S. and Chinese negotiators — including an American deputy defense secretary and a Chinese Foreign Ministry official — staked out tough positions Tuesday ahead of talks on the return of a U.S. spy plane and the collision that killed a Chinese fighter pilot. Tensions remain high between the two superpowers, even after the release of 24 U.S. crew members who were held for 11 days after making an emergency landing on Hainan island in the South China Sea. China has demanded an end to U.S. surveillance flights near its territory and says it wants to discuss how to avoid such incidents during Wfednesday’s talks at the Foreign Ministry. Both sides say they will review the cause of the collision. Beijing insists the EP-3 surveillance plane caused the April 1 crash and that Washington must take responsibility. U.S. officials say the Chinese F-8 fighter plane was probably at fault. The Bush administration has rejected the call for an end to the surveillance flights, saying it has the right to fly in international airspace. U.S. officials have made bringing the plane home their priority since the crew’s release. “We want our airplane back, and we’re going to make that point, and we would expect to get a response,” State Depart ment spokes man Richard Boucher said Tuesday, adding that he expected the matter to be addressed in the talks in Beijing. r\ « ~ ..... I___—....TTl.iia—J Blair McClelland/U.S. Navy The crew of the detained EP-3 "Aries II” aircraft boarded a plane to Hawaii for a military debriefing before being reunited with families and friends at the Whidbey Island Naval Air Station in Washington. ''r u - Undersecretary of Defense Peter F. Veiga, who heads the U.S. delegation, told reporters only that his side was seeking more information. “We’re here ... to meet with the Chinese government and exchange information regarding the ongoing situation with our reconnaissance aircraft,” Verga said Tuesday at Beijing’s airport. Six of the eight members of the U.S. team are military officers or Defense Department officials. They include an expert on the EP-3 and Army Brig. Gen. Neal Sealock, the U.S. Embassy military attache who served as chief contact with the crew during their captivity. China’s delegation will be led by Lu Shimin, director general of the Foreign Ministry’s North American mid Oceanic Affairs Department, spokeswoman Zhang Qiyue said. She said military officials would also be in the delegation, but gave SPYPLANE SEE PAGE 5 Abortion pill RU-486 stirring strong debate on college campuses by Darlene Superville Associated Press WASHINGTON — The debate over the abortion pill on college campuses isn’t just an academic exercise. Seven months after the Food and Drug Administration approved the abortion pill RU-486 (mifepristone) for use in the United Slates, many universities have chosen not to offer it, saying conditions for dispensing it are too onerous. It’s also apparent that some want to avoid the attention that distributing RU-486 might bring. But some students say the hands-off policy violates their rights. “If this is a legal, medical procedure, then it should be just as available to students as to the general public,” said Mike Ehlers, a Michigan State student representative. A survey of about 30 schools found one, Yale, offering RU-486. Many colleges outside of that survey, done by an anti-abortion group, also don’t offer RU-486, abortion-rights advocates say. “There’s absolutely no reason women shouldn’t have access.” said Giroline Barber, a junior and president of the Reproductive Rights Action League of Yale College. Michigan State University’s student assembly passed a resolution in February criticizing the school’s decision not to offer RU-486 as “an abridgment of students’ civil rights.” Campus officials prefer the clinical debate to the political one, focusing on the repeat doctor’s visits and potential complications and costs associated with administering the drug. A woman choosing tffis alternative to suigical abortion must see the doctor at least tltree times during a two-week period — to take the abortion pill, to be given a second drug that causes contractions that expel the embryo and to check that the pregnancy hits ended. “There is a lot of controversy surrounding RU-486 and we do not offer it,” said Laura Davenport, medical director for the University of Utah’s student health services. But at Yale, after the drug won FDA approval “it simply was added to the list of options. That’s it,” said Gila Reinstein, assistant director of public affairs. Israel temporarily seizes land from Palestinians in Gaza Strip by Pamela Sampson Associated Press GAZA CITY, Gaza Strip — With a heavy rocket barrage, Israel seized nearly a square mile of the Gaza Strip on Tuesday, retaking Palestinian-controlled territory for the first time since 1994 in retaliation for a mortar attack on a small Israeli desert town. An Israeli official, speaking on condition of anonymity, said Israeli troops would leave the pocket in northeastern Gaza overnight. The seizure of the land enraged Palestinians raid provoked rare criticism from the United States. Secretary of State Colin Powell called the action in Gaza “excessive and disproportionate” and said Israel should respect its commitment to the Palestinians. “The situation is threatening to escalate further, posing the risk of a broader conflict,” Powell said. Israel had initially said it could hold the territory — an area of orange groves and farmland — for months until Palestinian mortar fire stopped. Palestinian leader Yasser Arafat denounced the seizure as an “unforgivable crime” and said his people would “not kneel before gangs.” Palestinian security officials, also speaking on condition of anonymity, said U.S. officials told them the Israelis would withdraw from the area seized in Gaza. The Israeli assault came in response to mortar fire Monday night on Sderot, a working-class town of 24,000 about 2 1/2 miles east of Gaza. The town is a stronghold of support for Israeli Prime Minister Ariel Sharon, and liis sheep ranch is five miles away. The Islamic militant group Hamas claimed responsibility for the mortars, but Israel blamed Palestinian security forces. Flares lit up the sky Monday night as Israeli forces shelled and rocketed Palestinian police stations across the Gaza Strip, killing a policeman and injuring 36 other people. Soon after, troops crossed into the comer of Gaza closest to Sderot, seizing and tearing down abandoned Palestinian security posts. Under Israeli tank fire, army bulldozers razed orange groves outside the Palestinian town of Beit Hanoun, and Israeli troops built fortified positions. During the barrage, hundreds of Palestinians ran into the streets in Gaza City’s Rimal neighborhood, where rockets punched holes in the facade of a police headquarters. Rimal resident Ghada Skaik, whose bedroom window was shattered, said she spent a sleepless night. “If you go to bed mid you can’t feel safe, then where can you go mid feel safe?” she said. By daybreak, after Israeli troops settled into their new positions, tanks periodically fired toward Palestinians trying to approach the area. Palestinian medics carrying the body of a Palestinian policeman away from the rubble of a Beit Hanoun police compound were sent running by Israeli fire, at one point dropping to the ground to take cover. Earth’s reflection helps scientists gauge climate by Randolph Schmid Associated Press WASHINGTON — Scientists are using our planet’s ghostly reflection on the dark moon to help monitor climate. The glow, known as earthshine, helps researchers measure how much sunlight the Earth is reflecting, an important factor in determining global change. During a crescent moon, earthshine can be viewed with the naked eye, looking at the shaded portion of the moon. Leonardo da Vinci first explained the phenomenon, in which the moon acts as a giant mirror, showing the sunlight reflected from Earth. Scientists from the New Jersey Institute of Technology and the California Institute of Technology reported in the May 1 issue of Geophysical Research Letters that they used earthshine to measure the Earth’s reflectance. They concluded that the fraction of sunlight the planet reflects is currently 29.7 percent. “Earth’s climate is driven by the net sunlight that it absorbs,” said Philip R. Goode, leader of the New Jersey Institute of Technology team. “We have found surprisingly large — up to 20 percent — seasonal variations in Earth’s reflectance,” he said. If Errth reflected even one percent less light on average, the effect could be significant enough to be a concern with regard to global warming, the scientists said. Less light reflected could mean more absorbed on Eirth, resulting in warmer temperatures. In the early 20th century, the French astronomer Andre-Louis Danjon undertook the fust quantitative observations of earthshine. But the method lay dormant for nearly 50 years, until Caltech professor Steven E. Koonin described its potential in a 1991 paper. World Briefs ■ U.S. government fails to protect privacy on Web sites WASHINGTON (AP) — Dozens of federal Web sites use unauthorized software that tracks Internet users de spite policy rules that ban such infor mation-gathering, according to a re port to Congress. The true scope of the problem hasn’t been identified. The report said the National Aeronau tics and Space Administration could not even determine how many Web sites it operates, so investigators could not say how many of them might be using the tracking software. The report was culled front 16 agency audits, a third of the audits in the works. The other agencies are expected to release their findings within a few months, said Sen. Fred Thompson, R-Tenn„ chairman of the Senate Governmental Affairs Committee. ■ Russia’s NTV takeover worries independent media MOSCOW (AP) — The takeover of Russia's pioneering NTV television by a government-connected gas com pany leaves a dwindling number of in dependent Journalistic voices — none with NTV’s ability to reach most of Russia’s 144 million people scattered across 11 time zones. And the fate of one of those outlets, the newspaper Segodnyn, was in doubt after the abrupt announcement that Tuesday’s edition would not appettr. With all three nationwide channels connected to the government in some way, peo ple alternatively can turn to a few muckraking print publications and to NTV’s sister radio station, Eklto Moskvy. But time appears to be run ning out for several of those organiza tions ;ts well. ■ Double winners claim Pulitzer Prizes NEW YORK (AP) — Four news papers claimed double victories in the Pulitzer Prize competition, mid mi au thor won his second award for the same biography. The 2001 prizes, an nounced Monday by Columbia Uni versity, also saw a pair of winners hon ored for a single event: The day federal agents seized Elian Gonzalez. The breaking news award went to The Mi itnii Herald for deadline coverage of the seizure, mid the breaking news photography prize went to Alan Diaz of The Associated Press for his dramat ic photo of a rifle-toting agent taking custody of the child. The double win ners tliis year were the Chicago Tri bune, The New York Times, The Ore gonian of Portland and The Wall Street Journal. The Oregonian won the pub lic service Pulitzer for a study that found the U.S. Immigration and Natu ralization Service was detaining people without access to lawyers. Oregonian reporter Tom Hallman Jr.’s poignant profile of a disfigured youth was cho sen for the feature writing award. The newspaper has won three Pulitzers in the past two years. With a money-saving Eurail pass, you can make tracks in Europe wherever and whenev er the impulse moves you. A variety of Railpasses are available, including: Eurailpass Youth Flexi Travel any 10/15 days in 2 months (17 countries), $458/599* RER.ailEurope I Travel ^ America's Leader in Student Travel 1-800-2Council www.counciltravel.com ‘Must ho lindi.'H <Kju 20 oil fiisl day ol ItavcM LUNELLE* Monthly Contraceptive Injection medroxyprogesterone acetate and estradiol cypionate injectable suspension LUNELLE* Monthly Contraceptive Injection (like all hormonal contraceptives) is intended to prevent pregnancy. It does not prated against HIV infection (AIDS) and other sexually transmitted This summaiy contains important information about LUNELLE1* Morthly Contraceptive Injection. It is not meant to take the place ot dis cussions with your doctor and it cannot replace your doctors advice. Only your dodor can assess the benefits and risks to decide if LUNELLE" Monthly Contraceptive Injection is right (or you. Talk to your doctor or pharmacist, or other pre scribing healthcare professional, if you do not understand any of Ibis information on "if you want to know mote about LUNELLE" Monthly Contraceptive Injection. WHATB LUHElLr MONTHLY CTHTBA LUNELLE* Montnty Contracepfive Injection is a type of hormonal birth control that is given as an injection (a shot) in your arm. ttiigh. or buttock once a month to prevent pregnancy It contains hoimones which have effects similar to the natural hormones, estrogen and progesterone, produced in your body. Similar combinations ol hoimones are found in some ora) contraceptives also known as "birth control pills" or "the pill." When you receive your injections once a month as pre scribed. LUNEllE" Monthjy Contraceptive Injection is as effective as birth control pills. When given according to the prescribed schedule. LUNELLE" Monthly Contraceptive Injection is in which it feglvHSSdies raw shewn that when women receive LUNELLE" Monthly Contraceptive Injection according to the recom mended schedule, toe failure rate of this method ol Dirrn control is less man i % per year • Cigarette smoking increases the risk of serious cardiovascular side effects from hormonal contraceptive use. This risk increases with age and with heavy smok ing (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use hotmonal contra ceptives are strongly advised not to smoke. Some women shouW not use hotmonal contra ceptives For example, you should not take LUNELLE” Monthly Contraceptive Injection ii you are pregnant or thilik you may be pregnant. You should also not use LUNELLE" Monthly Contraceptive Injection ii you have any ot the fol lowing conditions: • A history ol heart attack ot stroke • Blood dots to the tegs (thrombophlebitis), lungs (pulmonary embolism), or eyes • A history of blood dots in the deep veins ol your legs • Chest pain (angina pectoris) • Known or suspected breast cancer or cancer of the lining ot the uterus, cervix or vagina • Unexplained vaginal bleeding (until a diag nosis is reached by your doctor) • Yellowing ot the whites ot the eyes or ot the skin (jaundice) during pregnmy or during previous use ol the pill or other hormonal contraceptives • Liver tumor (benign or cancerous) • Known or suspected pregnancy • Al letgy to any of the ingredients contained in LUNELLE” Monthly L'ontraceptive Injection • Ova age 35 and smoke 15 or more cigarettes per day Tell your health care provider it you have ever had any of these conditions. Your health care provider can recommend a safer method ol birth control. AflE THERE OTHER THINGS TO CQN StDER BEFORE TAKING LUNELLE™ MONTHLY CONTRACEPTIVE INJECTION? For the majority of women, hormonal contracep tives can be taken safely But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. Tell your health care provider it you have: • Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammo gram, strong family history ot breast cancer • Diabetes • Elevated cholesterol or biglycerides • High blood pressure • Migraine or other headaches or epilepsy • Mental depression • Gallbladder, heart or kidney disease • History of scanty or irregular menstrual periods • Smoke, especially if 35 years or older Women with any ot these conditions should be checked often by their health care provider it they choose to use LUNELLE* Monthly Conbacefkive Injection. Also, be sure to inform your doctor or health care provider it you smrtre or are on any medications. 1. RMt ot developing Mood dots, tart attacks, and strokes Blood clots and blockage of blood vessels are the most serious side effects ol taking hormonal con traceptives. In particular, blood clots can occur in the legs and can travel to the lungs aid can cause sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eve and mav cause blindness, double vision, or impaired vision If you take hormonal contraceptives such as LUNELLE" Monthly Contraceptive Injection and need elective surgery, need to stay in bed tor a prolonged illness, or have recently had a baby, you may be at risk of developing blood clots. Ycu stoild consult your doctor about slopping hor monal contraceptives three to lour weeks before surgery and not taking hormonal contraceptives lor two weeks after surgery or during bed rest You should also not lake hormonal contraceptives soon after delivery of a baby It is advisable to wail lor a! least lour weeks after delivery before using hormonal contraceptives such as LUNELLE™ Monthly Contraceptive Injection. (See also the section on Breast Feeding in WHAT PRECAU TIONS SHOULD BE FOLLOWED DURING THE USE OF LUNELLE MONTHLY CONTRACEPTIVE INJECTION?) Hoimonal contraceptives may also increase the tendency to develop strokes (stoppage or rupture of blood wssels m the brain) and angina pectoris and heart attacks (blockage ol blood vessels in the heart). Any of these conditions can cause death a disability. Smoking greatly increases the possibility ol devel oping blood clots or suffering heart attacks and strokes. Furthermore, smoking and the use of hor monal contraceptives greity increase the chances of developing and dying of heart disease, particu larly it you are over 35 years of age. 2. Gallbladder disease Hormonal contraceptive users probably have a greater risk man non-users of having gallbladder disease. 3. Liver tumors In rare cases, hormonal contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal c bleeding. In addition, a possible but not definite p association has been tound with hormonal contra- a ceptives and liver cancers in two studies, in which 1 a lew women who developed these wry rare can- p cets were found lo haw used hormonal contra- c ceptives lor long periods. Howewr, I her cancers a are extremely rare The chance of developing liver e cancer trom using hormonal contraceptives is Ihus It ewn rarer. t 4. Cancer of the reproductive organs and ( breasts a There is, at present, no contiimed evidence that " oral hormonal contraceptives increase the risk ot f cancer of the reproductive organs in human stud- « ies. Studies lo dale ol women taking the pill haw' c reported conflicting Wings on whether pill use * increases It* risk of developing cancer of the P breast Most of ttie studies on breast cancer and c pill use have tound no overall increase in the risk S of developing breast cancer, atttiougti some stud- k ies haw reported an increased risk ol developing ) breast cancer in certain groups ol women 1 Some studies have found an increase m the inci- 1 denceol cancer of the cervix in women who use C oral hormonal contraceptives. However, this find- a ing may be related to Mots other than the use ol l oral hormonal contraceptives. 1 Studies haw tound that women who used injectable hormonal contraceptives (Depo-Proveta Contraceptive Injection) had no increased overall ' risk ol developing cancer ot die breast, ovary, ' uterus, ot cervix. Howewr. women under 35 years ot age whose fits exposure to Depo-Proveta 1 Contraceptive Injection was within the previous 4 to 5 years may haw a slightly increased risk ol developing breast cancer similar to that seen with oral contraceptives. ' vvuiiibh wiiu use uuiiiwiui ufliudu^iiVK) onu have a strong (amity history ot breast cancer or 1 who have breast nodules or abnormal mammo gram should be closely followed by their doctors. 5. Changes in bone mineral density Use ot injectable hormonal contraceptives con taining the progesterone-type hormone found in LUNELLE" Monthly Contraceptive injection may , be associated with a decrease in the amount of mineral stored in your bones. This could increase your risk ot developing bone fractures. The rate ot , bone mineral loss is greatest in the early years ol use ot this type ot contraceptive, but after that, it begins lo resemble the normal rate of age-related bone mineral loss. 6. Allergic reactions , Severe allergic reactions have been reported in , some women using injectable hormonal contra- . cepthes containing the progesterone-type hor- j mone found in LUNELLF" Monthly Contraceptive ! Injection Allergic reactions occurring in women . using LUNELLE™ Monthly Contraceptive Injection have been mainly stun reactions, and not respira tory in nature Serious allergic reactions require 1 emergency medical treatment ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods ol birth control and pregnancy are associated with a risk of developing certain dis- \ eases that may lead to disability or death An esti- j mate of the number ol deahs associated with dif ferent methods ot birth control and pregnancy has been calculated. The risk ot death trom any birth control method is . less than the risk of childbirth, except tor oral hor- J monal contraceptive users over the age of 35 who smoke and oral hotmonal contraceptive users over the age of 40 even 9 they do not smoke. For . women aged 15 lo 39, the risk ot death was high est with pregnancy (7-26 deaths per 100.000 . women, depending on age). Among oral hoimon- , at rjjitiacepliw users who do not smoke, the risk j death is always lower than that associated with egnancy lor any age group, although over the )e ol 40, the risk increases to 32 deaths per B.OOO women, compared to 28 associated with egnancy al that age. However, for oral hormonal mtraceptive users who smoke and are over the ie of 35, the estimated number ol deaths iceeds those lor other methods ol birth control, a woman is over the age oMO and smokes, it estimated risk ol death is lour limes higher 17(100,000 women) than the estimated risk isociated with pregnancy (28(100.000 women) that age group, i Advisory Committee ol the FDA discussed (hit sue in 1989 and recommended that the benefits oral contraceptive use by healthy, non-smoking omen over 40 years ol age may outweigh Ihe jssibie risks. However, women ol all ages are tutioned to use the lowest dose oral contracep re that is effective, and are strongly advised not smoke. «ytwdoel«.MM#Haltase1-'^ (verse effects occur while you are taking JNELLP' Monthly Contraceptive Injection. Sharp chest pain, coughing of blood, or suddet shortness of breath (indicating a possible clot in the lung) Rain in the call (indicating a possible dot in the leg] Crushing chest pain or heaviness in the chest (indicating a possible heart attack) Sudden severe headache or vomiting, dizziness or tainting, disturbances of vision or speech, weakness, of numbness in an arm or leg (indicating a possible stroke) Sudden partial or complete loss of vision (indicating a possible clot in the eye) Breast lumps (indicating possible breast cancel or fibrocystic disease of me breast ask your doctor or health care brovider to show you hew to examine your breasts) Severe pain or tenderness in It* abdominal area (indicating a possibly ruptured liver tumor, ovarian cyst, or pregnancy outside It* uterus) Difficulty in sleeping, weakness, lack ol energy, fatigue, or change in mood (possibly indicatini severe depression) Jaundice ot a yellowring of the skin or eyeballs, accompanied frequently by lever, fatigue, loss ot appetite, dark-colored urine, or light-colored bowel movements (indicating possible liver problems) Persrslent pain, pus, or Weeding at the injecBon sit Unusually heavy vaginal bleeding THAT ARE THE POSSIBLE SIDE EFFECTS F LUNELLE™ MONTHLY CONTRACEP IVEIIUECTWHI? . Vaginal bleeding lost women using LUNELLE” Monthly ontraceptive Injection experience alteration ol renstrual bleeding. Bleeding patterns may vary om a single monlhly bleed to no bleeding at all r slight staining between menstrual periods to equent, prolonged, and/or unpredictable bleed ig In any given injection interval, approximately 0% ot women using LUNELLE" Monlhly ontraceptive Injection experience withdrawal feeding that begins 20-25 days alter the injec an. Withdrawal bleeding lasts more than 7 days 142% ol women during the first month ol use nd in 29% ol women a Ihe end ol one year ol se. In any given injection interval, approximately 5% ol women may have no bleeding a all and 0% may expenence bleeding or spotting al vari us times in (tie cycle Irregular bleeding often ccuts during the first lew monlhs of LUNaLF" tenthly Contraceptive Injection uge and may per a with continued use in up Ip one dvird ol omen. Your menstrua blood flrtrc may be hear ier or lighter, and there may he no bleeding, tower days ol bleeding, or more days of bleeding than what you have previously experienced. Such bleeding usually does not indie* any serious problems. II an altered bleeding pattern persists or the bleeding is severe, discuss it with your health care provider. There is also a small risk that (painful) cramps may be associated with bleeding. 2. Weight change Weight gain is a common side effect in women using LUNELLE” Monthly Contraceptive Injection The average expected weight gain is 4 pounds in the first year ol use Some women gain more than 10 to 20 pounds in the first year Women haw gained as much as 49 pounds or lost as much as 48 pounds in one year of use. Clinical trials showed wide variability in individual weight change with an increasing percentage ol LUNELLP Monthly Contraceptiw Injection users experiencing weight change in excess ol 10 and 20 pounds with continued treatment 3. Contact lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health care provider, 4. Fluid retention Hotmonai contraceptives may cause edema (fluid retention) with swelling ol the fingers or ankles and may raise your blood pressure If you experience lluid retention, contact your doctor or health care provider. 5. Other side effects Other side effects may include breast pain or ten derness. acne, change in appetite, nausea, headache, nervousness, depression, mood changes, changes in sexual desire, dizziness, loss of scalp hair, rash, and vaginal infections. If any ol these side effects bother you, call your health care provider. WHAT PRECAUTIONS SHQULD-BL _ FOLLOWED DURING USE OF LUNELLE^ 1. Missed periods and use of hormonal con trapontiuoc hofnro nr rlurinn oartu nrpnnanrv You may not menstruate regularly alter you receive an injection of LUNELLE™ Monthly Contraceptive Injection. It you have received your injections regularly and miss one menstrual peri od. be sure to inform your health care provider. The risk ot unexpected pregnancy tor women receiving injectable contraceptives as scheduled is very low. If you have not received your injections as scheduled and missed a menstrual period, or il you missed two consecutive menstrual periods, you may be pregnant Check with your health care provider immediately to determine whether you are pregnant. Do not continue the injections until you are sure you are not pregnant but use another method ot contraception. There is no conclusive evidence that oral hoimonal contraceptive use is associated with an increase in birth detects, when taken inadwrtenlly during early pregnancy. Nevertheless, hormonal contraceptives should not be used during pregnancy. With Depo-Proveta Contraceptive Injection, there haw been reports ot an increased risk of low birth weight and neonatal infant death or other health problems in infants conceived dose to the time ot injection. However, these pregnancies are uncom mon. Children exposed in the womb to one ot the hormones found in LUNELLE" Monthly Contraceptive Injection (MPA), and followed to adolescence, showed no evidence ol any adverse effects on their health including their physical, mental, sexual ot social development. If you think you may haw become pregnant while using LUNELLE" Monthly Contraceptrw Injection, see your health care provider as soon as possible. You should check with your health care provider about risks to your unborn child Irom any medica tion taken during pregnancy. 2. While breast feeding It you are breast feeding, consult your health care provider before starting hormonal contracep tives, including LUNELLE” Monthly Contraceptive Injection. Some of the drugs in hor monal contraceptives are passed on to the child in breast milk. A few adverse effects on the child have been reported, including yellowing ol the skin (jaundice) and breast enlargement. Inaddi lion, hormonal contraceptives may decrease the amount and quality ol your milk. To insure the best quantity and qualify ol your breast milk, you should wait until 6 weeks abet childbirth before you start using LUNaLE” Monthly Contraceptive Injection. It possible, do not use hormonal contra ceptives while breast feeding. Breast feeding provides only partial protection from becoming pregnant and this partial protec tion decreases significantly as you breast feed lot longer periods of time. You should use another method ol contraception white breast feeding and consider starting hormonal contraceptives only after you have weaned your child completely. 3. Laboratory tests It you are scheduted for any laboratory tests, tell your doctor you are taking a hormonal contracep tive. Certain blood tests may be attected by hor monal contraceptives 4. Drag Interactions Certain drugs may interact with hormonal contra ceptives to make them tess elfretive in preventing pregnancy or cause a change in bleeding patterns. Such drugs include aminoglutfthimide. ritampin, drugs used for epilepsy such as barbiturates (tor example, phenoparbital). carbamazepine, and phenytoin (Di Win is one brand ol this drug), phenylbutazone (Butazolidin is one brand), herbal products containing S. Johns Wort (hypericum perforatum), and possibly certain antibiotics. You may need to use an additional contraception method wtren you take drugs which can make hormonal contraceptives less effective. Drug inter action studies have not been conducted with 11 INFl IF* Mnnlhlv Cnnlracentw Iniedinn 5. Sexually transmitted diseases This product (like all hormonal contracep tives) is intended to prevent pregnancy. It does not protect against transmission ot HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital her pes. genital waits, gonorrhea, hepatitis B, and syphilis. 6. Weight change LUNELLE7* Monthly Contraceptive Injection may cause weight gain of more than 10 pounds. WHEN PQI GET MY LUNELLE^-MQMDL LUNELLF* Monthly Contraceptive Injection can only be effective if you receive your injections at the proper times. Flist Injection • Within the first 5 days of the start of your normal menstrual period. • If you are presently using another type of birth control, your health care provider will decide the best time for you to start LUNELLE7" Monthly Contraceptive Injection. This will help make sure you have continued contraceptive coverage. • If you have recently been pregnant or had a baby, discuss with your health care provider the best time for you to start LUNELLE7* Monthly Contraceptive Injection. Next Injections • LUNELLE7* Monthly Contraceptive Injection must be given monthly, every 28 to 30 days and no later than 33 days after your last injection. The time for your next injection is determined by the number of days sine# your previous injection, and not by the tiring or amount of your menstrual bleeding. Even il you do not have any menstrual bleed ing, you should still return once a month tor your injection ol LUNELLE” Monthly Contraceptive Ihjedion. • It is important mat you receive each ot your next injections at the right time. II you cannot receive your injection on lime, contad your health care provider to receive an earlier injection What Happens III Miss an Injection or Wait Longer than 33 Days Between Injections? • You could beome pregnant il you mtes your injection or wait longer than 33 days between injections. The more days you wailthe greater the risk that you could become pregnant • Ask your health care provider to recommend another type ol birth control (such as condoms or a spermicide) lor you to use. • Talk with your health care provider to find out when you should receive your next injection ol LUNELLE” Monthly Contraceptive Injection. • Your health care provider may do aitest to make sure you are not pregnant before giving you your next injection of LUNELLE" Monthly Contraceptive Injection Pregnancy Doe to Failure with LUNELLE” Monthly Contraceptive Injection The incidence ol failure with LUNELLE” Monthly Contraceptive Injection resulting in pregnancy te less than 1 percent (i.e., one pregnancy per 100 women per year) if given every month as directed N you think that you may be pregnant, be sure to call your health care provider. What It I Want te Become Pregnant? You will need to stop you monWy injections of LUNELLE” Monthly Contraceptive Injection Most women begin to produce eggsegain (and could become pregnant) atxxjt two to three months after their last injection. There may te some delay in becoming pregnant after you stop using hormonal contraceptives, inclu ding LUNELLE” Monlhly Contraceptive Injection. especially II yuu uu iieyuidi ineusuuoj cyuea before you started using hormonal contraceptives. There does not appear to be any increase in birth defects in newborn babies when pregnancy occur soon after slopping hormonal contraceptives. WHAT SHOULD I KNOW ABOUTA POSSIBLE OVERDOSE Of LUNELLE” SroL^We^Hvenatoi ^lemrtBdMwarp^ ingestion of large doses of ora! hormonal oontracepdres by young dttai Overdosage may case nausea and withdrawal bleeding in females. In case of cwrdosage. rate! your he* care provider or ptamacist Keep this and all drugs out ol the reach of children. OTHER INF0RMAT1PH Your health care provider will take a medical contraceptives. Ybu shouldSve'^arly physical examinations by your health care provider. Be sure to inform your health care provider it there is a family history of any of the conditions listed previ ously in this leaflet. Be sure to keep all appoint ments with your health care provider, because this is a time to determine if there are early signs of side effects of hormonal contraceptive use. If you want more information about hormonal contracep tives, ask your health care provider or pharmacist lor a more technical leaflet called the Prescribing Information that you may wish to read. Rxonly: Manufactured by: Pharmacia & Upjohn Company Kalamazoo, Ml 49001. USA CB-2-S rfk Lunelle■ kwed monthly contraceptive injedion n«]ratyDfDgBiannaatilB&es>3fioltYpaMn|actaUeaqiraan